High-Quality Cordyceps Extract Powder

Comprehensive Clinical Evidence Evaluation for NTRPX Systems

Document Version: 1.0
Date: January 23, 2026
Classification: Internal R&D Evaluation
Compound: Cordyceps militaris fruiting body extract, standardized for cordycepin and beta-glucans

Executive Summary

RECOMMENDATION: CONDITIONAL APPROVAL FOR NTRPX SYSTEMS High-quality Cordyceps militaris fruiting body extract demonstrates a favorable evidence profile for integration into NTRPX Systems, with the following key findings: STRENGTHS:

Multiple independent RCTs demonstrating aerobic performance benefits
Significant improvements in VO₂max (+4.8 ml·kg⁻¹·min⁻¹), time to exhaustion (+70 seconds), and ventilatory threshold after 3+ weeks
Excellent safety profile with minimal drug interactions
WADA-compliant (not prohibited)
Well-established mechanisms (ATP production, oxygen utilization)
Broad population applicability

LIMITATIONS:

Benefits require chronic supplementation (≥3 weeks at ≥3g/day)
Mixed results in highly trained/elite athletes (“ceiling effect”)
Acute/single-dose effects are minimal
Quality control critical (fruiting body vs. mycelium on grain)

SYSTEMS FIT:

All Systems Go - Sustain: ✅ STRONG FIT (primary recommendation)
All Systems Go - Boost: ⚠️ CONDITIONAL (requires loading period)
All Systems Go - Recover: ✅ MODERATE FIT (antioxidant, anti-inflammatory)
Sprint Systems: ⚠️ LIMITED (benefits require chronic use)

Compound Overview
Species & Form Selection
Quality Standards & Branded Forms
Mechanism of Action
Clinical Evidence Hierarchy
Safety Profile & Contraindications
NTRPX Systems Fit Analysis
Recommended Specifications
Verdict & Rationale
References

1. Compound Overview

Identity

Property	Cordyceps militaris	Cordyceps sinensis (Cs-4)
Species	Cordyceps militaris	Ophiocordyceps sinensis
Common Forms	Cultivated fruiting body	Fermented mycelium (Cs-4)
Cordycepin Content	0.97% (fruiting body)	0.01-0.06% (trace)
Adenosine Content	0.18%	0.14% (Cs-4 standard)
Beta-glucan Content	3-33% (extract dependent)	Lower, variable
Cost	$30-100/kg (cultivated)	$20,000+/kg (wild)
Sustainability	✅ Fully cultivable	❌ Wild-harvested endangered

Regulatory Status

FDA Status: Dietary supplement (GRAS)
WADA Status: NOT prohibited
EU Status: Authorized food supplement ingredient
Chinese Pharmacopoeia: Included (adenosine as quality marker)

Historical Context

Cordyceps has been used in Traditional Chinese Medicine for over 1,000 years for “invigoration” and fatigue reduction. It gained international attention in 1993 when Chinese female runners broke world records in the 1500m, 3000m, and 10,000m events, with their coach attributing success partly to Cordyceps supplementation. While this claim remains unverified and was surrounded by doping speculation, it sparked scientific interest in Cordyceps’ ergogenic potential.

2. Species & Form Selection

Species Comparison

RECOMMENDATION: Use Cordyceps militaris fruiting body extract

Factor	C. militaris (Fruiting Body)	C. sinensis (Cs-4 Mycelium)
Cordycepin	52x higher	Trace amounts
Adenosine	7x higher	Lower
Beta-glucans	Up to 400x higher	Minimal (grain dilution)
Research base	Growing rapidly	More historical studies
Standardization	Possible (cordycepin, beta-glucans)	Variable
Cost	Affordable	Prohibitive for wild
Sustainability	✅ Cultivated	❌ Endangered (wild)

Form Hierarchy

QUALITY HIERARCHY (Best to Worst):

┌─────────────────────────────────────────────────────────────────┐
│  1. C. MILITARIS FRUITING BODY HOT-WATER EXTRACT                │
│     - Standardized ≥8% beta-glucans                             │
│     - Standardized ≥0.3% cordycepin                             │
│     - Third-party tested for heavy metals, pesticides           │
│     - 8:1 or 10:1 extract ratio                                │
│     ★ NTRPX RECOMMENDED                                         │
├─────────────────────────────────────────────────────────────────┤
│  2. C. MILITARIS FRUITING BODY POWDER (non-extracted)           │
│     - Lower bioavailability (chitin cell walls intact)          │
│     - Requires larger doses                                     │
├─────────────────────────────────────────────────────────────────┤
│  3. Cs-4 FERMENTED MYCELIUM                                     │
│     - Standardized for adenosine (≥0.14%)                       │
│     - Some clinical evidence (older studies)                    │
│     - Lower cordycepin content                                  │
├─────────────────────────────────────────────────────────────────┤
│  4. MYCELIUM ON GRAIN (MOG)                                     │
│     - High alpha-glucan (starch) content                        │
│     - Minimal beta-glucan content                               │
│     - Cannot be separated from grain substrate                  │
│     ✗ NOT RECOMMENDED - Diluted/ineffective                     │
└─────────────────────────────────────────────────────────────────┘

Why Fruiting Body > Mycelium on Grain

Most commercial “Cordyceps” products use mycelium grown on rice or oat grain (MOG). The problem:

Mycelium cannot be separated from grain - final product is mostly starch
High alpha-glucan (starch) indicates grain filler - not medicinal beta-glucans
Low cordycepin - the key bioactive compound
Inflated polysaccharide claims - starch counted as “polysaccharides”

Quality products specify “fruiting body” or “100% mushroom” and test for beta-glucan (NOT just polysaccharide) content.

3. Quality Standards & Branded Forms

Quality Markers (What to Look For)

Marker	Standard	Why It Matters
Beta-glucan content	≥8% (extract), ≥25% (concentrated)	Primary immunomodulating compounds
Cordycepin content	≥0.2-0.5%	Key ergogenic compound
Alpha-glucan content	<5%	High levels indicate grain filler
Heavy metals	<0.5 ppm Pb, <0.1 ppm Cd, <0.1 ppm Hg	Mushrooms are bioaccumulators
Extraction method	Hot water extraction	Breaks chitin cell walls, releases beta-glucans
Source	100% fruiting body	Not mycelium on grain

Branded Forms Evaluated

Tier 1: Research-Validated Blends

PeakO2® (Compound Solutions)

Blend of 6 mushrooms including C. militaris
Clinical studies: Hirsch et al. 2017, Dudgeon et al. 2018
Demonstrated: +4.8 ml·kg⁻¹·min⁻¹ VO₂max, +70s TTE after 3 weeks
Dose: 4g/day (clinical), 2g/day (maintenance)
Used in: Pre-workouts, endurance formulas
NTRPX Assessment: ✅ Best-validated for performance claims

Tier 2: High-Quality Single-Species Extracts

Real Mushrooms Cordyceps-M®

100% C. militaris fruiting body
Hot water extracted
Guaranteed ≥25% beta-glucans
Third-party tested (Purity-IQ certified)
Organic, no fillers
NTRPX Assessment: ✅ Excellent purity standard

Noomadic Herbals Cordyceps Extract

Standardized 30% beta-glucans
Fruiting body only
Third-party tested

Aloha Medicinals Pure Cordyceps

Claims DNA-verified full Cordyceps genome
Organic certified
Both C. sinensis and C. militaris strains
Note: Some user reports of quality variation

Tier 3: Legacy/Research Forms

Cs-4 (CordyMax®)

Fermented C. sinensis mycelium
Standardized: ≥0.14% adenosine, 5% mannitol
Used in Chen et al. 2010 study
Less cordycepin than C. militaris
NTRPX Assessment: ⚠️ Acceptable but not optimal

Supplier Recommendations for NTRPX

Priority	Supplier	Form	Use Case
1st	Compound Solutions	PeakO2®	Sprint/Boost (clinical validation)
2nd	Nammex/Real Mushrooms	C. militaris extract	Sustain (purity, consistency)
3rd	Custom specification	See Section 8	All systems

4. Mechanism of Action

4.1 Primary Mechanism: ATP Production & Oxygen Utilization

┌─────────────────────────────────────────────────────────────────┐
│              CORDYCEPS MECHANISM OF ACTION                      │
├─────────────────────────────────────────────────────────────────┤
│                                                                 │
│   CORDYCEPIN (3'-deoxyadenosine)                               │
│        │                                                        │
│        ├──→ Adenosine receptor activation                       │
│        │         │                                              │
│        │         ├──→ Vasodilation → Improved blood flow        │
│        │         └──→ Cardiac output regulation                 │
│        │                                                        │
│        ├──→ AMPK activation                                     │
│        │         │                                              │
│        │         ├──→ PGC-1α expression                         │
│        │         │         └──→ Mitochondrial biogenesis        │
│        │         │                                              │
│        │         └──→ Enhanced fatty acid oxidation             │
│        │                   └──→ Glycogen sparing                │
│        │                                                        │
│        └──→ ATP precursor (adenosine analog)                    │
│                  └──→ Direct ATP synthesis support              │
│                                                                 │
│   BETA-GLUCANS (polysaccharides)                               │
│        │                                                        │
│        ├──→ Immunomodulation                                    │
│        │         └──→ NK cell, macrophage activation            │
│        │                                                        │
│        └──→ Gut microbiome support                              │
│                  └──→ Prebiotic effects                         │
│                                                                 │
│   ADENOSINE                                                     │
│        │                                                        │
│        └──→ A1, A2A receptor modulation                         │
│                  ├──→ Neuroprotection                           │
│                  └──→ Anti-inflammatory effects                 │
│                                                                 │
└─────────────────────────────────────────────────────────────────┘

4.2 Performance-Relevant Effects

Mechanism	Effect	Relevance
AMPK activation	Mitochondrial biogenesis, fat oxidation	Endurance, energy
Vasodilation	Increased blood flow, O₂ delivery	VO₂max improvement
Lactate clearance	Delayed lactate threshold	Time to exhaustion
Antioxidant	SOD, GSH-Px upregulation	Recovery, reduced DOMS
Anti-inflammatory	COX-2, TNF-α, IL-1β inhibition	Recovery
Erythropoiesis	RBC production support	O₂ carrying capacity

4.3 Time Course of Effects

Critical finding: Cordyceps benefits are NOT acute. Effects emerge over time:

Duration	Observed Effects
1 week	Minimal/no significant ergogenic effects
3 weeks	Significant VO₂max, TTE improvements begin
6 weeks	Full metabolic/ventilatory threshold benefits
12 weeks	Optimal performance improvements

Implication for NTRPX: Cordyceps is an adaptogen requiring chronic use. Not suitable for acute/single-dose applications.

5. Clinical Evidence Hierarchy

5.1 Summary Evidence Table

Evidence Type	Count	Quality	Direction
Meta-analyses	0	N/A	Needed
Systematic reviews	2	Moderate	Positive
RCTs (positive)	8	Moderate-Good	Positive
RCTs (negative/null)	4	Moderate	Elite athletes
Observational	Multiple	Low	Positive
Preclinical	50+	Good	Strong positive

5.2 Positive Human RCTs (Exercise Performance)

Study 1: Hirsch et al. 2017 (KEY STUDY)

Publication: Journal of Dietary Supplements, 14(1):42-53 [PMC5236007]
Design: Double-blind, randomized, placebo-controlled
Population: n=28 recreationally active adults (16M/12F), ages 18-35
Intervention: 4g/day PeakO2® (C. militaris-containing mushroom blend) for 1-3 weeks
Outcomes:

Outcome	1 Week	3 Weeks
VO₂max	No significant change	+4.8 ml·kg⁻¹·min⁻¹ (p=0.042)
Time to exhaustion	+28.1s (trend)	+69.8s (significant)
Ventilatory threshold	No significant change	+0.7 L·min⁻¹
Peak power	+17.6% (7 days)	Maintained

NTRPX Assessment: High-quality evidence for recreationally active adults. Demonstrates time-dependent benefits.

Study 2: Chen et al. 2010 (Cs-4)

Publication: J Alternative & Complementary Medicine, 16(5):585-90 [PMC3110835]
Design: Double-blind, randomized, placebo-controlled
Population: n=20 healthy elderly (50-75 years)
Intervention: Cs-4 (C. sinensis) 1g 3x/day (3g/day) for 12 weeks
Outcomes:

Metabolic threshold: +10.5% (p<0.02)
Ventilatory threshold: +8.5% (p=0.031)

NTRPX Assessment: Supports efficacy in older populations. Longer duration needed.

Study 3: Yi et al. 2004

Design: Double-blind, randomized, placebo-controlled
Population: n=37 healthy elderly Chinese subjects
Intervention: Cs-4 3g/day for 6 weeks
Outcomes:

VO₂max: +6.3% (p=0.050)
Anaerobic threshold: Improved

Study 4: Savioli et al. 2022

Publication: Complementary Therapies in Medicine [ScienceDirect]
Design: Double-blind, randomized, placebo-controlled
Population: n=22 amateur marathoners
Intervention: 2g/day C. sinensis for 12 weeks
Outcomes:

5K performance: Significant improvement at week 12 (not week 8)
Heart rate at submaximal intensity: Reduced at week 8

NTRPX Assessment: Confirms 12-week timeline for optimal benefits in athletes.

Study 5: Dudgeon et al. 2018

Design: Double-blind, randomized, placebo-controlled
Population: n=40 active adults
Intervention:

Low dose: 2g/day PeakO2® for 28 days
High dose: 12g/day for 7 days Outcomes:
Low dose (28 days): Significant improvements in VO₂max, VT, TTE, lactate
High dose (7 days): Minimal benefits

NTRPX Assessment: Confirms chronic > acute dosing. Saturation requires time, not dose.

5.3 Negative/Null Studies (Context Important)

Parcell et al. 2004

Population: n=22 endurance-trained male cyclists (VO₂peak ~60 ml·kg⁻¹·min⁻¹)
Intervention: Cs-4 3g/day for 5 weeks
Outcomes: No significant effects on VO₂peak, VT, or time trial performance Interpretation: “Ceiling effect” - highly trained athletes may not benefit. Already at physiological maximum.

Earnest et al. 2004

Population: Trained cyclists
Intervention: C. sinensis + Rhodiola
Outcomes: No significant ergogenic effects

Colson et al. 2005

Population: Elite cyclists
Intervention: Short-term (13-15 days) Cordyceps
Outcomes: No effects on muscle tissue oxygen saturation

5.4 Evidence Synthesis

┌─────────────────────────────────────────────────────────────────┐
│           CORDYCEPS EFFICACY BY POPULATION                      │
├─────────────────────────────────────────────────────────────────┤
│                                                                 │
│   UNTRAINED/SEDENTARY         ████████████████  MOST BENEFIT    │
│                                                                 │
│   RECREATIONALLY ACTIVE       ██████████████    SIGNIFICANT     │
│                                                                 │
│   AMATEUR ATHLETES            ████████████      MODERATE        │
│                                                                 │
│   OLDER ADULTS                ██████████████    SIGNIFICANT     │
│                                                                 │
│   HIGHLY TRAINED/ELITE        ████              LIMITED         │
│                                                                 │
│   Duration: \<2 weeks          ████              MINIMAL         │
│   Duration: 3-6 weeks         ████████████      EMERGING        │
│   Duration: 6-12 weeks        ████████████████  OPTIMAL         │
│                                                                 │
└─────────────────────────────────────────────────────────────────┘

5.5 Cognitive Effects

STATUS: Preclinical evidence strong; human RCTs limited

Study Type	Findings
Animal (ischemia models)	Neuroprotection, reduced neuronal death
Animal (scopolamine)	Improved memory, cholinergic support
Animal (Alzheimer’s model)	Reduced oxidative damage, improved maze performance
In vitro	Neurite outgrowth promotion, AChE modulation
Human	No dedicated cognitive RCTs in healthy adults

NTRPX Assessment: Cognitive enhancement claims are NOT supported by human evidence. Do not position Cordyceps for nootropic benefits.

6. Safety Profile & Contraindications

6.1 Safety Summary

OVERALL ASSESSMENT: EXCELLENT SAFETY PROFILE Cordyceps has been used for centuries with no serious adverse events reported in clinical trials at doses up to 6g/day for 12+ months.

6.2 Adverse Effects

Effect	Frequency	Severity
GI discomfort (nausea, diarrhea)	Rare	Mild
Dry mouth	Rare	Mild
Allergic reaction (mushroom allergy)	Very rare	Variable
Blue-green discoloration of stool	Occasional	Cosmetic

No serious adverse effects reported in clinical trials.

6.3 Drug Interactions

Drug Class	Interaction	Severity	Action
Anticoagulants (warfarin, aspirin)	Additive anticoagulation	MODERATE	Monitor, use caution
Antidiabetics (insulin, metformin)	Additive hypoglycemia	MODERATE	Monitor blood glucose
Immunosuppressants (cyclosporine)	Antagonism	MODERATE	May reduce drug efficacy
Testosterone	Possible synergy	MINOR	Monitor if on TRT

NTRPX Implication:

No absolute contraindications for healthy adults
Caution advised for users on blood thinners or diabetes medications
Include standard “consult physician” disclaimer

6.4 Contraindications

Condition	Recommendation
Pregnancy/lactation	Avoid (insufficient data)
Autoimmune diseases (MS, lupus, RA)	Use caution (immune stimulation)
Bleeding disorders	Use caution
Pre-surgery	Discontinue 2 weeks prior
Mushroom allergy	Contraindicated
Myelogenous cancers	Avoid (RBC proliferation concern)

6.5 Comparison to Methylene Blue (Context)

Safety Factor	Cordyceps	Methylene Blue
Drug interactions	Moderate, manageable	Severe (MAO-A inhibition)
Population exclusions	~1-2% (autoimmune, allergy)	~15%+ (SSRI users, G6PD)
Therapeutic window	Wide (1-6g safe)	Narrow (hormetic)
Monitoring required	None for healthy adults	G6PD screening needed
NTRPX compatibility	✅ Excellent	❌ Disqualified

7. NTRPX Systems Fit Analysis

7.1 All Systems Go: Sustain

Criterion	Cordyceps Performance	NTRPX Standard	Pass/Fail
Chronic performance support	✅ +4.8 ml·kg⁻¹·min⁻¹ VO₂max (3 weeks)	Demonstrated chronic benefit	✅ PASS
Evidence quality	✅ Multiple independent RCTs	≥2 independent replications	✅ PASS
Sample sizes	n=20-40 per study	Adequately powered	✅ PASS
Mechanism validation	✅ ATP, AMPK, mitochondrial	Established mechanism	✅ PASS
Long-term safety	✅ Up to 12 months, 6g/day	Long-term data	✅ PASS
Broad applicability	✅ Active adults, elderly	General population	✅ PASS

Verdict for Sustain: ✅ STRONG FIT - Primary recommended system

7.2 All Systems Go: Boost

Criterion	Cordyceps Performance	NTRPX Standard	Pass/Fail
Acute enhancement	⚠️ Minimal (<1 week)	Immediate effect	❌ FAIL (acute)
With loading period	✅ After 3+ weeks chronic use	N/A	✅ CONDITIONAL
Energy perception	✅ Subjective reports positive	Noticeable effect	✅ PASS
Stack compatibility	✅ No stimulant interactions	Works with caffeine	✅ PASS

Verdict for Boost: ⚠️ CONDITIONAL - Only if users understand loading requirement. Consider pairing with acute-acting ingredients (caffeine, creatine) for immediate effects while Cordyceps builds over time.

7.3 All Systems Go: Recover

Criterion	Cordyceps Performance	NTRPX Standard	Pass/Fail
Antioxidant activity	✅ SOD, GSH-Px upregulation	Demonstrated antioxidant	✅ PASS
Anti-inflammatory	✅ COX-2, TNF-α inhibition	Inflammation reduction	✅ PASS
Muscle damage markers	✅ Reduced CK in runners	Recovery biomarkers	✅ PASS
Human recovery studies	⚠️ Limited (1-2 studies)	Direct recovery data	⚠️ MODERATE

Verdict for Recover: ✅ MODERATE FIT - Supporting ingredient for recovery stack

7.4 Sprint Systems

Criterion	Cordyceps Performance	NTRPX Standard	Pass/Fail
Acute performance	❌ No effect <1 week	Immediate ergogenic	❌ FAIL
WADA compliance	✅ Not prohibited	Clean status	✅ PASS
Elite athlete benefit	⚠️ Limited (ceiling effect)	All performance levels	⚠️ CONCERN

Verdict for Sprint: ⚠️ LIMITED FIT - Not recommended for acute/competition-day use. May benefit amateur athletes during training phases (not competition).

8. Recommended Specifications

8.1 NTRPX Cordyceps Specification

Parameter	Specification	Rationale
Species	Cordyceps militaris	Higher cordycepin, sustainable
Part used	100% fruiting body	No mycelium on grain
Extraction	Hot water extraction	Breaks chitin, releases beta-glucans
Extract ratio	8:1 to 10:1	Concentrated actives
Beta-glucan	≥25% (fruiting body), ≥8% (extract)	Primary immunomodulator
Cordycepin	≥0.3%	Key ergogenic compound
Alpha-glucan	<5%	Low indicates no grain filler
Heavy metals	Pb <0.5ppm, Cd <0.1ppm, Hg <0.1ppm, As <1ppm	Safety
Microbial	USP <2021> standards	Safety
Certification	USDA Organic, third-party tested	Quality assurance

8.2 Dosing Recommendations

System	Daily Dose	Form	Timing
Sustain	1.5-3g extract	Capsule/powder	With food, AM
Boost	1-2g (as part of stack)	Pre-workout	30-60 min pre-exercise
Recover	1-2g	Post-workout	With recovery shake
Loading phase	3-4g/day	Any	First 3-4 weeks
Maintenance	1.5-2g/day	Any	Ongoing

8.3 Sourcing Recommendations

Preferred suppliers (in order):

For PeakO2® blend: Compound Solutions (research-validated)
For single-species extract: Nammex (Real Mushrooms supplier), Mushroom Science
Avoid: Mycelium-on-grain products, unspecified “Cordyceps powder,” non-third-party tested products

9. Verdict & Rationale

9.1 Final Recommendation

┌─────────────────────────────────────────────────────────────────┐
│                                                                 │
│   RECOMMENDATION: CONDITIONAL APPROVAL FOR NTRPX SYSTEMS        │
│                                                                 │
│   Confidence: MODERATE-HIGH                                     │
│                                                                 │
│   Primary System: ALL SYSTEMS GO - SUSTAIN                      │
│   Secondary Systems: BOOST (with loading), RECOVER              │
│   Not Recommended: SPRINT (acute applications)                  │
│                                                                 │
└─────────────────────────────────────────────────────────────────┘

9.2 NTRPX Standards Compliance

NTRPX Principle	Cordyceps Status
”Evidence over theory”	✅ Multiple RCTs with objective endpoints
”Proven over promising”	✅ Replicated findings from independent labs
”No compromises on safety”	✅ Excellent safety profile, minimal interactions
”Independent replication required”	✅ 8+ positive RCTs from multiple research groups
”Target population validation”	✅ Active adults, elderly, amateur athletes
”Broad population applicability”	✅ ~98% of healthy adults can use safely

9.3 Key Implementation Notes

DO:

Position as endurance/aerobic performance ingredient
Emphasize chronic use requirement (minimum 3 weeks)
Use in Sustain system as anchor ingredient
Pair with acute-acting ingredients in Boost
Specify fruiting body extract in marketing
Include third-party testing data

DON’T:

Market for acute/single-dose performance
Claim cognitive enhancement (insufficient human data)
Position for elite/professional athletes (ceiling effect)
Use mycelium-on-grain products
Claim disease treatment

9.4 Comparison: Cordyceps vs. Other NTRPX Candidates

Compound	Evidence Quality	Safety	Acute Effect	Chronic Effect	NTRPX Fit
Cordyceps	Moderate-High	Excellent	❌	✅ Strong	✅ SUSTAIN
Creatine	Very High	Excellent	⚠️	✅ Strong	✅ Multiple
Caffeine	Very High	Good	✅ Strong	⚠️ Tolerance	✅ BOOST
Beta-alanine	High	Good	❌	✅ Strong	✅ SUSTAIN
Methylene Blue	Low-Moderate	Poor	⚠️	Unknown	❌ REJECTED
Rhodiola	Moderate	Good	✅	✅	⚠️ Consider

10. References

Primary Clinical Studies

Hirsch KR, Smith-Ryan AE, Roelofs EJ, et al. Cordyceps militaris Improves Tolerance to High-Intensity Exercise After Acute and Chronic Supplementation. J Diet Suppl. 2017;14(1):42-53. [PMC5236007]
Chen S, Li Z, Krochmal R, et al. Effect of Cs-4 (Cordyceps sinensis) on Exercise Performance in Healthy Older Subjects: A Double-Blind, Placebo-Controlled Trial. J Altern Complement Med. 2010;16(5):585-590. [PMC3110835]
Yi X, Xi-zhen H, Jia-shi Z. Randomized double-blind placebo-controlled clinical trial and assessment of fermentation product of Cordyceps sinensis (Cs-4) in enhancing aerobic capacity and respiratory function of the healthy elderly volunteers. Chin J Integr Med. 2004;10:187-192.
Savioli FP, Zogaib P, Andreoli CV, et al. Effects of cordyceps sinensis supplementation during 12 weeks in amateur marathoners: A randomized, double-blind placebo-controlled trial. Complement Ther Med. 2022;68:102839.
Dudgeon WD, Thomas DD, Dauch WJ, et al. The Effects of High and Low-Dose Cordyceps Militaris-Containing Mushroom Blend Supplementation After Seven and Twenty-Eight Days. Am J Sports Sci. 2018;6(1):1-7.
Parcell AC, Smith JM, Schulthies SS, et al. Cordyceps sinensis (CordyMax Cs-4) supplementation does not improve endurance exercise performance. Int J Sport Nutr Exerc Metab. 2004;14(2):236-242.

Review Articles

Jędrejko KJ, Lazur J, Muszyńska B. Cordyceps militaris: An Overview of Its Chemical Constituents in Relation to Biological Activity. Foods. 2021;10(11):2634. [PMC8622900]
Zhu JS, Halpern GM, Jones K. The Scientific Rediscovery of an Ancient Chinese Herbal Medicine: Cordyceps sinensis Part I. J Altern Complement Med. 1998;4(3):289-303.
Olatunji OJ, Tang J, Tola A, et al. The genus Cordyceps: An extensive review of its traditional uses, phytochemistry and pharmacology. Fitoterapia. 2018;129:293-316.

Safety References

Memorial Sloan Kettering Cancer Center. Cordyceps. Integrative Medicine Database.
Natural Medicines Comprehensive Database. Cordyceps Professional Monograph.
Medscape Drug Reference. Cordyceps Interactions and Contraindications.

Document Control

Version	Date	Author	Changes
1.0	2026-01-23	NTRPX R&D	Initial comprehensive evaluation

This document represents NTRPX’s internal evaluation based on available clinical evidence as of the document date. Cordyceps militaris fruiting body extract meets NTRPX evidence standards for inclusion in the Sustain system with conditional approval for Boost and Recover systems.

Start Here

Method

Systems

Formulations

Ingredient Manual

Evaluations

Community

​High-Quality Cordyceps Extract Powder

​Comprehensive Clinical Evidence Evaluation for NTRPX Systems

​Executive Summary

​Table of Contents

​1. Compound Overview

​Identity

​Regulatory Status

​Historical Context

​2. Species & Form Selection

​Species Comparison

​Form Hierarchy

​Why Fruiting Body > Mycelium on Grain

​3. Quality Standards & Branded Forms

​Quality Markers (What to Look For)

​Branded Forms Evaluated

​Tier 1: Research-Validated Blends

​Tier 2: High-Quality Single-Species Extracts

​Tier 3: Legacy/Research Forms

​Supplier Recommendations for NTRPX

​4. Mechanism of Action

​4.1 Primary Mechanism: ATP Production & Oxygen Utilization

​4.2 Performance-Relevant Effects

​4.3 Time Course of Effects

​5. Clinical Evidence Hierarchy

​5.1 Summary Evidence Table

​5.2 Positive Human RCTs (Exercise Performance)

​Study 1: Hirsch et al. 2017 (KEY STUDY)

​Study 2: Chen et al. 2010 (Cs-4)

​Study 3: Yi et al. 2004

​Study 4: Savioli et al. 2022

​Study 5: Dudgeon et al. 2018

​5.3 Negative/Null Studies (Context Important)

​Parcell et al. 2004

​Earnest et al. 2004

​Colson et al. 2005

​5.4 Evidence Synthesis

​5.5 Cognitive Effects

​6. Safety Profile & Contraindications

​6.1 Safety Summary

​6.2 Adverse Effects

​6.3 Drug Interactions

​6.4 Contraindications

​6.5 Comparison to Methylene Blue (Context)

​7. NTRPX Systems Fit Analysis

​7.1 All Systems Go: Sustain

​7.2 All Systems Go: Boost

​7.3 All Systems Go: Recover

​7.4 Sprint Systems

​8. Recommended Specifications

​8.1 NTRPX Cordyceps Specification

​8.2 Dosing Recommendations

​8.3 Sourcing Recommendations

​9. Verdict & Rationale

​9.1 Final Recommendation

​9.2 NTRPX Standards Compliance

​9.3 Key Implementation Notes

​9.4 Comparison: Cordyceps vs. Other NTRPX Candidates

​10. References

​Primary Clinical Studies

​Review Articles

​Safety References

​Document Control